Skip to main content
Erschienen in: PharmacoEconomics 7/2009

01.07.2009 | Review Article

Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines

verfasst von: Dr Natasha K. Stout, Amy B. Knudsen, Chung Yin Kong, Pamela M. McMahon, G. Scott Gazelle

Erschienen in: PharmacoEconomics | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Increasingly, computer simulation models are used for economic and policy evaluation in cancer prevention and control. A model’s predictions of key outcomes, such as screening effectiveness, depend on the values of unobservable natural history parameters. Calibration is the process of determining the values of unobservable parameters by constraining model output to replicate observed data. Because there are many approaches for model calibration and little consensus on best practices, we surveyed the literature to catalogue the use and reporting of these methods in cancer simulation models.
We conducted a MEDLINE search (1980 through 2006) for articles on cancer-screening models and supplemented search results with articles from our personal reference databases. For each article, two authors independently abstracted pre-determined items using a standard form. Data items included cancer site, model type, methods used for determination of unobservable parameter values and description of any calibration protocol. All authors reached consensus on items of disagreement. Reviews and non-cancer models were excluded. Articles describing analytical models, which estimate parameters with statistical approaches (e.g. maximum likelihood) were catalogued separately.Models that included unobservable parameters were analysed and classified by whether calibration methods were reported and if so, the methods used.
The review process yielded 154 articles that met our inclusion criteria and, of these, we concluded that 131 may have used calibration methods to determine model parameters. Although the term ‘calibration’ was not always used, descriptions of calibration or ‘model fitting’ were found in 50% (n = 66) of the articles, with an additional 16% (n = 21) providing a reference to methods. Calibration target data were identified in nearly all of these articles. Other methodological details, such as the goodness-of-fit metric, were discussed in 54% (n = 47 of 87) of the articles reporting calibration methods, while few details were provided on the algorithms used to search the parameter space.
Our review shows that the use of cancer simulation modelling is increasing, although thorough descriptions of calibration procedures are rare in the published literature for these models. Calibration is a key component of model development and is central to the validity and credibility of subsequent analyses and inferences drawn from model predictions. To aid peer-review and facilitate discussion of modelling methods, we propose a standardized Calibration Reporting Checklist for model documentation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ramsey SD, McIntosh M, Etzioni RD, et al. Simulation modeling of outcomes and cost-effectiveness. Hematol Oncol Clin North Am 2000 Aug; 14 (4): 925–38PubMedCrossRef Ramsey SD, McIntosh M, Etzioni RD, et al. Simulation modeling of outcomes and cost-effectiveness. Hematol Oncol Clin North Am 2000 Aug; 14 (4): 925–38PubMedCrossRef
2.
Zurück zum Zitat Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 2007; 25: 203–8PubMedCrossRef Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 2007; 25: 203–8PubMedCrossRef
3.
Zurück zum Zitat Feuer EJ, Etzioni RD, Cronin KA, et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec; 13: 421–42PubMedCrossRef Feuer EJ, Etzioni RD, Cronin KA, et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec; 13: 421–42PubMedCrossRef
4.
Zurück zum Zitat Goldie SJ. Chapter 15: public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr 2003; 31: 102–10PubMedCrossRef Goldie SJ. Chapter 15: public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr 2003; 31: 102–10PubMedCrossRef
5.
Zurück zum Zitat Goldie SJ, Goldhaber-Fiebert JD, Garnett G. Chapter 18: public health policy for cervical cancer prevention. The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006 Aug 31; 24 (S3): 155–63CrossRef Goldie SJ, Goldhaber-Fiebert JD, Garnett G. Chapter 18: public health policy for cervical cancer prevention. The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006 Aug 31; 24 (S3): 155–63CrossRef
6.
Zurück zum Zitat Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043–53PubMedCrossRef Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043–53PubMedCrossRef
7.
Zurück zum Zitat Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896–904PubMedCrossRef Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896–904PubMedCrossRef
8.
Zurück zum Zitat Yeh JM, Kuntz KM, Ezzati M, et al. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 2008 May 1; 17 (5): 1179–87PubMedCrossRef Yeh JM, Kuntz KM, Ezzati M, et al. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 2008 May 1; 17 (5): 1179–87PubMedCrossRef
9.
Zurück zum Zitat Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002 May 8; 287 (18): 2372–81PubMedCrossRef Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002 May 8; 287 (18): 2372–81PubMedCrossRef
10.
Zurück zum Zitat Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997 Jun; 18 (3): 251–70PubMedCrossRef Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997 Jun; 18 (3): 251–70PubMedCrossRef
11.
Zurück zum Zitat Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000 June 15, 2000; 151 (12): 1158–71 Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000 June 15, 2000; 151 (12): 1158–71
12.
Zurück zum Zitat Law AM, Kelton WD. Simulation modeling and analysis. 3rd ed. Boston (MA): McGraw-Hill, 2000 Law AM, Kelton WD. Simulation modeling and analysis. 3rd ed. Boston (MA): McGraw-Hill, 2000
13.
Zurück zum Zitat Clarke LD, Plevritis SK, Boer R, et al. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 2006; 36: 96–105PubMedCrossRef Clarke LD, Plevritis SK, Boer R, et al. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 2006; 36: 96–105PubMedCrossRef
14.
Zurück zum Zitat Banks J, editor. Handbook of simulation: principles, methodology, advances, applications, and practice. New York: John Wiley & Sons. Inc., 1998 Banks J, editor. Handbook of simulation: principles, methodology, advances, applications, and practice. New York: John Wiley & Sons. Inc., 1998
15.
Zurück zum Zitat Bruning JL, Kintz BL. Computational handbook of statistics. 4th ed. Boston (MA): Allyn & Bacon, 1997 Bruning JL, Kintz BL. Computational handbook of statistics. 4th ed. Boston (MA): Allyn & Bacon, 1997
16.
Zurück zum Zitat Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965; 7 (4): 308–13CrossRef Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965; 7 (4): 308–13CrossRef
17.
Zurück zum Zitat Kirkpatrick S, Gelatt CD, Vecchi MP. Optimization by simulated annealing. Science 1983; 220 (4598): 671–80PubMedCrossRef Kirkpatrick S, Gelatt CD, Vecchi MP. Optimization by simulated annealing. Science 1983; 220 (4598): 671–80PubMedCrossRef
18.
Zurück zum Zitat Press WH, Teukolsky SA, Vetterling WT, et al. Numerical recipes in C++. 2nd ed. New York (NY): Cambridge University Press, 2002 Press WH, Teukolsky SA, Vetterling WT, et al. Numerical recipes in C++. 2nd ed. New York (NY): Cambridge University Press, 2002
19.
Zurück zum Zitat Wong DF, Leong HW, Liu CL. Simulated annealing for VLSI design. Boston (MA): Kluwer Academic Publishers, 1988CrossRef Wong DF, Leong HW, Liu CL. Simulated annealing for VLSI design. Boston (MA): Kluwer Academic Publishers, 1988CrossRef
20.
Zurück zum Zitat Holland JH. Adaptation in natural and artificial systems. Ann Arbor (MI): University of Michigan Press, 1975 Holland JH. Adaptation in natural and artificial systems. Ann Arbor (MI): University of Michigan Press, 1975
21.
Zurück zum Zitat Goldberg DE. Genetic algorithms in search, optimization and machine learning. Boston (MA): Kluwer Academic Publishers, 1989 Goldberg DE. Genetic algorithms in search, optimization and machine learning. Boston (MA): Kluwer Academic Publishers, 1989
22.
Zurück zum Zitat Manikas TW, Cain JT. Genetic algorithms vs. simulated annealing: a comparison of approaches for solving the circuit partitioning problem. Pittsburgh (PA): University of Pittsburgh, 1996 Manikas TW, Cain JT. Genetic algorithms vs. simulated annealing: a comparison of approaches for solving the circuit partitioning problem. Pittsburgh (PA): University of Pittsburgh, 1996
23.
Zurück zum Zitat Ingber L, Rosen B. Genetic algorithms and very fast simulated annealing: a comparison. Math Comput Model 1992; 16 (11): 87–100CrossRef Ingber L, Rosen B. Genetic algorithms and very fast simulated annealing: a comparison. Math Comput Model 1992; 16 (11): 87–100CrossRef
24.
Zurück zum Zitat Glover F. Tabu search: part I. ORSA J Computing 1989; 1 (3): 190–206CrossRef Glover F. Tabu search: part I. ORSA J Computing 1989; 1 (3): 190–206CrossRef
25.
26.
Zurück zum Zitat Kong CY, McMahon PM, Gazelle GS. Calibration of disease simulation models using an engineering approach. Value Health 2009; 12 (4): 521–9PubMedCrossRef Kong CY, McMahon PM, Gazelle GS. Calibration of disease simulation models using an engineering approach. Value Health 2009; 12 (4): 521–9PubMedCrossRef
27.
Zurück zum Zitat Baker RD. Use of a mathematical model to evaluate breast cancer screening policy. Health Care Manage Sci 1998 Oct; 1 (2): 103–13CrossRef Baker RD. Use of a mathematical model to evaluate breast cancer screening policy. Health Care Manage Sci 1998 Oct; 1 (2): 103–13CrossRef
28.
Zurück zum Zitat Beckett JR, Kotre CJ, Michaelson JS. Analysis of benefit: risk ratio and mortality reduction for the UK Breast Screening Programme. Br J Radiol 2003 May; 76 (905): 309–20PubMedCrossRef Beckett JR, Kotre CJ, Michaelson JS. Analysis of benefit: risk ratio and mortality reduction for the UK Breast Screening Programme. Br J Radiol 2003 May; 76 (905): 309–20PubMedCrossRef
29.
Zurück zum Zitat Beemsterboer PM, Warmerdam PG, Boer R, et al. Radiation risk of mammography related to benefit in screening programmes: a favourable balance? J Med Screen 1998; 5 (2): 81–7PubMed Beemsterboer PM, Warmerdam PG, Boer R, et al. Radiation risk of mammography related to benefit in screening programmes: a favourable balance? J Med Screen 1998; 5 (2): 81–7PubMed
30.
Zurück zum Zitat Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant treatment on mortality from breast cancer. N Engl J Med 2005 Oct 27; 353 (17): 1784–92PubMedCrossRef Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant treatment on mortality from breast cancer. N Engl J Med 2005 Oct 27; 353 (17): 1784–92PubMedCrossRef
31.
Zurück zum Zitat Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006; 36: 30–6PubMedCrossRef Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006; 36: 30–6PubMedCrossRef
32.
Zurück zum Zitat Blanchard K, Colbert JA, Puri D, et al. Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer 2004 Aug 1; 101 (3): 495–507PubMedCrossRef Blanchard K, Colbert JA, Puri D, et al. Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer 2004 Aug 1; 101 (3): 495–507PubMedCrossRef
33.
Zurück zum Zitat Boer R, de Koning H, Threlfall A, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998 Aug 8; 317 (7155): 376–9PubMedCrossRef Boer R, de Koning H, Threlfall A, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998 Aug 8; 317 (7155): 376–9PubMedCrossRef
34.
Zurück zum Zitat Boer R, de Koning H, van Oortmarssen G, et al. Stage distribution at first and repeat examinations in breast cancer screening. J Med Screen 1999; 6 (3): 132–8PubMed Boer R, de Koning H, van Oortmarssen G, et al. Stage distribution at first and repeat examinations in breast cancer screening. J Med Screen 1999; 6 (3): 132–8PubMed
35.
Zurück zum Zitat Carter R, Glasziou P, van Oortmarssen G, et al. Cost-effectiveness of mammographic screening in Australia. Aust J Public Health 1993 Mar; 17 (1): 42–50PubMedCrossRef Carter R, Glasziou P, van Oortmarssen G, et al. Cost-effectiveness of mammographic screening in Australia. Aust J Public Health 1993 Mar; 17 (1): 42–50PubMedCrossRef
36.
Zurück zum Zitat Carter KJ, Castro F, Kessler E, et al. A computer model for the study of breast cancer. Comput Biol Med 2003 Jul; 33: 345–60PubMedCrossRef Carter KJ, Castro F, Kessler E, et al. A computer model for the study of breast cancer. Comput Biol Med 2003 Jul; 33: 345–60PubMedCrossRef
37.
Zurück zum Zitat Carter KJ, Castro F, Kessler E, et al. Simulation of breast cancer screening: quality assessment of two protocols. J Healthc Qual 2004 Nov-Dec; 26 (6): 31–8PubMedCrossRef Carter KJ, Castro F, Kessler E, et al. Simulation of breast cancer screening: quality assessment of two protocols. J Healthc Qual 2004 Nov-Dec; 26 (6): 31–8PubMedCrossRef
38.
Zurück zum Zitat Castro F, Carter KJ, Kessler E, et al. The relation of breast cancer staging to screening protocol compliance: a computer simulation study. Comput Biol Med 2005 Feb; 35 (2): 91–101PubMedCrossRef Castro F, Carter KJ, Kessler E, et al. The relation of breast cancer staging to screening protocol compliance: a computer simulation study. Comput Biol Med 2005 Feb; 35 (2): 91–101PubMedCrossRef
39.
Zurück zum Zitat Chia YL, Salzman P, Plevritis SK, et al. Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res 2004 Dec; 13 (6): 507–24PubMedCrossRef Chia YL, Salzman P, Plevritis SK, et al. Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res 2004 Dec; 13 (6): 507–24PubMedCrossRef
40.
Zurück zum Zitat Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med 2005 Oct 30; 24 (20): 3123–38PubMedCrossRef Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med 2005 Oct 30; 24 (20): 3123–38PubMedCrossRef
41.
Zurück zum Zitat Connor RJ, Boer R, Prorok PC, et al. Investigation of design and bias issues in case-control studies of cancer screening using microsimulation. Am J Epidemiol 2000 May 15; 151 (10): 991–8PubMedCrossRef Connor RJ, Boer R, Prorok PC, et al. Investigation of design and bias issues in case-control studies of cancer screening using microsimulation. Am J Epidemiol 2000 May 15; 151 (10): 991–8PubMedCrossRef
42.
Zurück zum Zitat de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991 Oct 21; 49: 531–7CrossRef de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991 Oct 21; 49: 531–7CrossRef
43.
Zurück zum Zitat de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995 Aug 16; 87 (16): 1217–23PubMedCrossRef de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995 Aug 16; 87 (16): 1217–23PubMedCrossRef
44.
Zurück zum Zitat Eddy DM. Screening for breast cancer. Ann Intern Med 1989; 111 (5): 389–99PubMed Eddy DM. Screening for breast cancer. Ann Intern Med 1989; 111 (5): 389–99PubMed
45.
Zurück zum Zitat Feldstein M, Zelen M. Inferring the natural time history of breast cancer: implications for tumor growth rate and early detection. Breast Cancer Res Treat 1984; 4: 3–10PubMedCrossRef Feldstein M, Zelen M. Inferring the natural time history of breast cancer: implications for tumor growth rate and early detection. Breast Cancer Res Treat 1984; 4: 3–10PubMedCrossRef
46.
Zurück zum Zitat Fett MJ. Computer modelling of the Swedish two county trial of mammographic screening and trade offs between participation and screening interval. J Med Screen 2001; 8 (1): 39–45PubMedCrossRef Fett MJ. Computer modelling of the Swedish two county trial of mammographic screening and trade offs between participation and screening interval. J Med Screen 2001; 8 (1): 39–45PubMedCrossRef
47.
Zurück zum Zitat Fracheboud J, Groenewoud JH, Boer R, et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 2006 Apr 15; 118 (8): 2020–5PubMedCrossRef Fracheboud J, Groenewoud JH, Boer R, et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 2006 Apr 15; 118 (8): 2020–5PubMedCrossRef
48.
Zurück zum Zitat Fryback DG, Stout NK, Rosenberg MA, et al. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr 2006; 36: 37–47PubMedCrossRef Fryback DG, Stout NK, Rosenberg MA, et al. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr 2006; 36: 37–47PubMedCrossRef
49.
Zurück zum Zitat Hanin LG, Miller A, Zorin AV, et al. The University of Rochester model of breast cancer detection and survival. J Natl Cancer Inst Monogr 2006; 36: 66–78PubMedCrossRef Hanin LG, Miller A, Zorin AV, et al. The University of Rochester model of breast cancer detection and survival. J Natl Cancer Inst Monogr 2006; 36: 66–78PubMedCrossRef
50.
Zurück zum Zitat Hsieh HJ, Chen TH, Chang SH. Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan. Stat Med 2002 Nov 30; 21 (22): 3369–82PubMedCrossRef Hsieh HJ, Chen TH, Chang SH. Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan. Stat Med 2002 Nov 30; 21 (22): 3369–82PubMedCrossRef
51.
Zurück zum Zitat Hunter DJ, Drake SM, Shortt SE, et al. Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002–2021. Cancer Detect Prev 2004; 28 (6): 453–60PubMedCrossRef Hunter DJ, Drake SM, Shortt SE, et al. Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002–2021. Cancer Detect Prev 2004; 28 (6): 453–60PubMedCrossRef
52.
Zurück zum Zitat Jacobi CE, Jonker MA, Nagelkerke NJ, et al. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care [letter]. J Med Genet 2003 Jul; 40 (7): e83CrossRef Jacobi CE, Jonker MA, Nagelkerke NJ, et al. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care [letter]. J Med Genet 2003 Jul; 40 (7): e83CrossRef
53.
Zurück zum Zitat Jacobi CE, Nagelkerke NJ, van Houwelingen JH, et al. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Cancer Epidemiol Biomarkers Prev 2006 Mar; 15 (3): 429–36PubMedCrossRef Jacobi CE, Nagelkerke NJ, van Houwelingen JH, et al. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Cancer Epidemiol Biomarkers Prev 2006 Mar; 15 (3): 429–36PubMedCrossRef
54.
Zurück zum Zitat Jansen JT, Zoetelief J. MBS: a model for risk benefit analysis of breast cancer screening. Br J Radiol 1995 Feb; 68 (806): 141–9PubMedCrossRef Jansen JT, Zoetelief J. MBS: a model for risk benefit analysis of breast cancer screening. Br J Radiol 1995 Feb; 68 (806): 141–9PubMedCrossRef
55.
Zurück zum Zitat Jansen JT, Zoetelief J. Assessment of lifetime gained as a result of mammographic breast cancer screening using a computer model. Br J Radiol 1997 Jun; 70 (834): 619–28PubMed Jansen JT, Zoetelief J. Assessment of lifetime gained as a result of mammographic breast cancer screening using a computer model. Br J Radiol 1997 Jun; 70 (834): 619–28PubMed
56.
Zurück zum Zitat Jansen JT, Zoetelief J. Optimisation of mammographic breast cancer screening using a computer simulation model. Eur J Radiol 1997 Feb; 24 (2): 137–44PubMedCrossRef Jansen JT, Zoetelief J. Optimisation of mammographic breast cancer screening using a computer simulation model. Eur J Radiol 1997 Feb; 24 (2): 137–44PubMedCrossRef
57.
Zurück zum Zitat Knox EG. Evaluation of a proposed breast cancer screening regimen. BMJ 1988 Sep 10; 297 (6649): 650–4PubMedCrossRef Knox EG. Evaluation of a proposed breast cancer screening regimen. BMJ 1988 Sep 10; 297 (6649): 650–4PubMedCrossRef
58.
Zurück zum Zitat Koscielny S, Tubiana M, Valleron AJ. A simulation model of the natural history of human breast cancer. Br J Cancer 1985 Oct; 52 (4): 515–24PubMedCrossRef Koscielny S, Tubiana M, Valleron AJ. A simulation model of the natural history of human breast cancer. Br J Cancer 1985 Oct; 52 (4): 515–24PubMedCrossRef
59.
Zurück zum Zitat Lee S, Zelen M. A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr 2006; 36: 79–86PubMedCrossRef Lee S, Zelen M. A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr 2006; 36: 79–86PubMedCrossRef
60.
Zurück zum Zitat Mandelblatt JS, Schechter CB, Yabroff KR, et al. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004 Jul 1; 22 (13): 2554–66PubMedCrossRef Mandelblatt JS, Schechter CB, Yabroff KR, et al. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004 Jul 1; 22 (13): 2554–66PubMedCrossRef
61.
Zurück zum Zitat Mandelblatt J, Schechter CB, Lawrence W, et al. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr 2006; 36: 47–55PubMedCrossRef Mandelblatt J, Schechter CB, Lawrence W, et al. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr 2006; 36: 47–55PubMedCrossRef
62.
Zurück zum Zitat Manton KG, Stallard E. Demographics (1950–1987) of breast cancer in birth cohorts of older women. J Gerontol 1992 Nov; 47 Spec No: 32–42PubMedCrossRef Manton KG, Stallard E. Demographics (1950–1987) of breast cancer in birth cohorts of older women. J Gerontol 1992 Nov; 47 Spec No: 32–42PubMedCrossRef
63.
Zurück zum Zitat Michaelson JS, Halpern E, Kopans DB. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology 1999 Aug; 212 (2): 551–60PubMed Michaelson JS, Halpern E, Kopans DB. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology 1999 Aug; 212 (2): 551–60PubMed
64.
Zurück zum Zitat Michaelson JS, Satija S, Moore R, et al. Estimates of breast cancer growth rate and sojourn time from screening database information. J Wom Imag 2003 Feb; 5 (1): 11–9CrossRef Michaelson JS, Satija S, Moore R, et al. Estimates of breast cancer growth rate and sojourn time from screening database information. J Wom Imag 2003 Feb; 5 (1): 11–9CrossRef
65.
Zurück zum Zitat Michaelson JS, Satija S, Moore R, et al. Estimates of the sizes at which breast cancers become detectable on mammographic and clinical grounds. J Wom Imag 2003 Feb; 5 (1): 3–10CrossRef Michaelson JS, Satija S, Moore R, et al. Estimates of the sizes at which breast cancers become detectable on mammographic and clinical grounds. J Wom Imag 2003 Feb; 5 (1): 3–10CrossRef
66.
Zurück zum Zitat Myles JP, Nixon RM, Duffy SW, et al. Bayesian evaluation of breast cancer screening using data from two studies. Stat Med 2003 May 30; 22 (10): 1661–74PubMedCrossRef Myles JP, Nixon RM, Duffy SW, et al. Bayesian evaluation of breast cancer screening using data from two studies. Stat Med 2003 May 30; 22 (10): 1661–74PubMedCrossRef
67.
Zurück zum Zitat Okubo I, Glick H, Frumkin H, et al. Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 1991 Apr 15; 67 (8): 2021–9PubMedCrossRef Okubo I, Glick H, Frumkin H, et al. Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 1991 Apr 15; 67 (8): 2021–9PubMedCrossRef
68.
Zurück zum Zitat Paci E, Boer R, Zappa M, et al. A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy. Eur J Cancer 1995; 31A (3): 348–53CrossRef Paci E, Boer R, Zappa M, et al. A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy. Eur J Cancer 1995; 31A (3): 348–53CrossRef
69.
Zurück zum Zitat Plevritis SK. A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Math Biosci 2001 Jun; 171 (2): 155–78PubMedCrossRef Plevritis SK. A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Math Biosci 2001 Jun; 171 (2): 155–78PubMedCrossRef
70.
Zurück zum Zitat Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006 May 24; 295 (20): 2374–84PubMedCrossRef Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006 May 24; 295 (20): 2374–84PubMedCrossRef
71.
Zurück zum Zitat Plevritis SK, Sigal BM, Salzman P, et al. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 2006; 36: 86–95PubMedCrossRef Plevritis SK, Sigal BM, Salzman P, et al. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 2006; 36: 86–95PubMedCrossRef
72.
Zurück zum Zitat Plevritis SK, Salzman P, Sigal BM, et al. A natural history model of stage progression applied to breast cancer. Stat Med 2006; 26 (3): 581–95CrossRef Plevritis SK, Salzman P, Sigal BM, et al. A natural history model of stage progression applied to breast cancer. Stat Med 2006; 26 (3): 581–95CrossRef
73.
Zurück zum Zitat Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics 2005 Dec; 61 (4): 992–9PubMedCrossRef Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics 2005 Dec; 61 (4): 992–9PubMedCrossRef
74.
Zurück zum Zitat Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 2005 Oct; 6 (4): 604–14PubMedCrossRef Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 2005 Oct; 6 (4): 604–14PubMedCrossRef
75.
Zurück zum Zitat Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006 Jun 7; 98 (11): 774–82PubMedCrossRef Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006 Jun 7; 98 (11): 774–82PubMedCrossRef
76.
Zurück zum Zitat Szeto KL, Devlin NJ. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Health Policy 1996 Nov; 38 (2): 101–15PubMedCrossRef Szeto KL, Devlin NJ. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Health Policy 1996 Nov; 38 (2): 101–15PubMedCrossRef
77.
Zurück zum Zitat Tan SYGL, van Oortmarssen GJ, de Koning HJ, et al. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006; 36: 56–65PubMedCrossRef Tan SYGL, van Oortmarssen GJ, de Koning HJ, et al. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006; 36: 56–65PubMedCrossRef
78.
Zurück zum Zitat Tubiana M, Koscielny S. The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys 1990 Nov; 19 (5): 1117–20PubMedCrossRef Tubiana M, Koscielny S. The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys 1990 Nov; 19 (5): 1117–20PubMedCrossRef
79.
Zurück zum Zitat van der Maas PJ, de Koning HJ, van Ineveld BM, et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989 Jun 15; 43 (6): 1055–60PubMedCrossRef van der Maas PJ, de Koning HJ, van Ineveld BM, et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989 Jun 15; 43 (6): 1055–60PubMedCrossRef
80.
Zurück zum Zitat van Oortmarssen GJ, Habbema JD, Lubbe JT, et al. A model-based analysis of the HIP project for breast cancer screening. Int J Cancer 1990 Aug 15; 46 (2): 207–13PubMedCrossRef van Oortmarssen GJ, Habbema JD, Lubbe JT, et al. A model-based analysis of the HIP project for breast cancer screening. Int J Cancer 1990 Aug 15; 46 (2): 207–13PubMedCrossRef
81.
Zurück zum Zitat van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer 1990 Oct 1; 66 (7): 1601–12PubMedCrossRef van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer 1990 Oct 1; 66 (7): 1601–12PubMedCrossRef
82.
Zurück zum Zitat Vervoort MM, Draisma G, Fracheboud J, et al. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004 Jul 19; 91 (2): 242–7PubMed Vervoort MM, Draisma G, Fracheboud J, et al. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004 Jul 19; 91 (2): 242–7PubMed
83.
Zurück zum Zitat Berkhof J, de Bruijne MC, Zielinski GD, et al. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 2005 Jun 10; 115 (2): 268–75PubMedCrossRef Berkhof J, de Bruijne MC, Zielinski GD, et al. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 2005 Jun 10; 115 (2): 268–75PubMedCrossRef
84.
Zurück zum Zitat Berkhof J, de Bruijne MC, Zielinski GD, et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006 Apr 1; 118 (7): 1759–68PubMedCrossRef Berkhof J, de Bruijne MC, Zielinski GD, et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006 Apr 1; 118 (7): 1759–68PubMedCrossRef
85.
Zurück zum Zitat Eddy DM. The frequency of cervical cancer screening: comparison of a mathematical model with empirical data. Cancer 1987 Sep 1; 60 (5): 1117–22PubMedCrossRef Eddy DM. The frequency of cervical cancer screening: comparison of a mathematical model with empirical data. Cancer 1987 Sep 1; 60 (5): 1117–22PubMedCrossRef
86.
Zurück zum Zitat Eddy DM. Screening for cervical cancer. Ann Intern Med 1990 Aug 1; 113 (3): 214–26PubMed Eddy DM. Screening for cervical cancer. Ann Intern Med 1990 Aug 1; 113 (3): 214–26PubMed
87.
Zurück zum Zitat Goldie SJ, Weinstein MC, Kuntz KM, et al. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999 Jan 19; 130 (2): 97–107PubMed Goldie SJ, Weinstein MC, Kuntz KM, et al. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999 Jan 19; 130 (2): 97–107PubMed
88.
Zurück zum Zitat Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001 Jun 27; 285 (24): 3107–15PubMedCrossRef Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001 Jun 27; 285 (24): 3107–15PubMedCrossRef
89.
Zurück zum Zitat Goldie SJ, Kim JJ, Wright TCJ. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004 Apr; 103 (4): 619–31PubMedCrossRef Goldie SJ, Kim JJ, Wright TCJ. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004 Apr; 103 (4): 619–31PubMedCrossRef
90.
Zurück zum Zitat Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004 Apr 21; 96 (8): 604–15PubMedCrossRef Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004 Apr 21; 96 (8): 604–15PubMedCrossRef
91.
Zurück zum Zitat Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005 Nov 17; 353 (20): 2158–68PubMedCrossRef Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005 Nov 17; 353 (20): 2158–68PubMedCrossRef
92.
Zurück zum Zitat Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989 Jul; 60 (1): 132–41PubMedCrossRef Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989 Jul; 60 (1): 132–41PubMedCrossRef
93.
Zurück zum Zitat Gustafsson L, Adami HO. Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer 1990 Jun; 61 (6): 903–8PubMedCrossRef Gustafsson L, Adami HO. Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer 1990 Jun; 61 (6): 903–8PubMedCrossRef
94.
Zurück zum Zitat Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control 1992 Mar; 3 (2): 125–36PubMedCrossRef Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control 1992 Mar; 3 (2): 125–36PubMedCrossRef
95.
Zurück zum Zitat Gyrd-Hansen D, Holund B, Andersen P. A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Policy 1995 Oct; 34 (1): 35–51PubMedCrossRef Gyrd-Hansen D, Holund B, Andersen P. A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Policy 1995 Oct; 34 (1): 35–51PubMedCrossRef
96.
Zurück zum Zitat Habbema JD, van Oortmarssen GJ, Lubbe JT, et al. Model building on the basis of Dutch cervical cancer screening data. Maturitas 1985 May; 7 (1): 11–20PubMedCrossRef Habbema JD, van Oortmarssen GJ, Lubbe JT, et al. Model building on the basis of Dutch cervical cancer screening data. Maturitas 1985 May; 7 (1): 11–20PubMedCrossRef
97.
Zurück zum Zitat Habbema JDF, Lubbe JTN, van Oortmarssen GJ, et al. A simulation approach to cost-effectiveness and cost-benefit calculations of screening for the early detection of disease. Eur J Oper Res 1987 May; 29 (2): 159–66CrossRef Habbema JDF, Lubbe JTN, van Oortmarssen GJ, et al. A simulation approach to cost-effectiveness and cost-benefit calculations of screening for the early detection of disease. Eur J Oper Res 1987 May; 29 (2): 159–66CrossRef
98.
Zurück zum Zitat Helfand M, O’Connor GT, Zimmer-Gembeck M, et al. Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) on the incidence of invasive cervical cancer. Med Care 1992 Dec; 30 (12): 1067–82PubMedCrossRef Helfand M, O’Connor GT, Zimmer-Gembeck M, et al. Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) on the incidence of invasive cervical cancer. Med Care 1992 Dec; 30 (12): 1067–82PubMedCrossRef
99.
Zurück zum Zitat Kim JJ, Wright TCJ, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002 May 8; 287 (18): 2382–90PubMedCrossRef Kim JJ, Wright TCJ, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002 May 8; 287 (18): 2382–90PubMedCrossRef
100.
Zurück zum Zitat Kim JJ, Leung GM, Woo PP, et al. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. J Public Health (Oxf) 2004 Jun; 26 (2): 130–7CrossRef Kim JJ, Leung GM, Woo PP, et al. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. J Public Health (Oxf) 2004 Jun; 26 (2): 130–7CrossRef
101.
Zurück zum Zitat Knox EG. A simulation system for screening procedures. In: McLachlan G, editor. Future and present indicatives, problems and progress in medical care. 9th rev. Oxford: Nuffield Provincial Hospitals Trust, Oxford University Press, 1973: 17–55 Knox EG. A simulation system for screening procedures. In: McLachlan G, editor. Future and present indicatives, problems and progress in medical care. 9th rev. Oxford: Nuffield Provincial Hospitals Trust, Oxford University Press, 1973: 17–55
102.
Zurück zum Zitat Koong SL, Yen AM, Chen TH. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006; 13 Suppl. 1: S44–7 Koong SL, Yen AM, Chen TH. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006; 13 Suppl. 1: S44–7
103.
Zurück zum Zitat Koopmanschap MA, Lubbe KT, van Oortmarssen GJ, et al. Economic aspects of cervical cancer screening. Soc Sci Med 1990; 30 (10): 1081–7PubMedCrossRef Koopmanschap MA, Lubbe KT, van Oortmarssen GJ, et al. Economic aspects of cervical cancer screening. Soc Sci Med 1990; 30 (10): 1081–7PubMedCrossRef
104.
Zurück zum Zitat Kulasingam SL, Myers ER, Lawson HW, et al. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 2006 Feb; 107 (2 Pt 1): 321–8PubMedCrossRef Kulasingam SL, Myers ER, Lawson HW, et al. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 2006 Feb; 107 (2 Pt 1): 321–8PubMedCrossRef
105.
Zurück zum Zitat Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002 Oct 2; 94 (19): 1469–83PubMedCrossRef Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002 Oct 2; 94 (19): 1469–83PubMedCrossRef
106.
Zurück zum Zitat Mandelblatt J, Lawrence W, Yi B, et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women. Arch Intern Med 2004 Feb 9; 164: 245–7CrossRef Mandelblatt J, Lawrence W, Yi B, et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women. Arch Intern Med 2004 Feb 9; 164: 245–7CrossRef
107.
Zurück zum Zitat Matsunaga G, Tsuji I, Sato S, et al. Cost-effective analysis of mass screening for cervical cancer in Japan. J Epidemiol 1997 Sep; 7 (3): 135–41PubMedCrossRef Matsunaga G, Tsuji I, Sato S, et al. Cost-effective analysis of mass screening for cervical cancer in Japan. J Epidemiol 1997 Sep; 7 (3): 135–41PubMedCrossRef
108.
Zurück zum Zitat Office of Technology Assessment. The costs and effectiveness of screening for cervical cancer in elderly women: background paper, OTA-BP-H-65. Washington, DC: U.S. Congress, 1990 Office of Technology Assessment. The costs and effectiveness of screening for cervical cancer in elderly women: background paper, OTA-BP-H-65. Washington, DC: U.S. Congress, 1990
109.
Zurück zum Zitat Parkin DM. A computer simulation model for the practical planning of cervical cancer screening programmes. Br J Cancer 1985 Apr; 51 (4): 551–68PubMedCrossRef Parkin DM. A computer simulation model for the practical planning of cervical cancer screening programmes. Br J Cancer 1985 Apr; 51 (4): 551–68PubMedCrossRef
110.
Zurück zum Zitat Parkin DM, Moss SM. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. J Epidemiol Community Health 1986 Jun; 40 (2): 143–53PubMedCrossRef Parkin DM, Moss SM. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. J Epidemiol Community Health 1986 Jun; 40 (2): 143–53PubMedCrossRef
111.
Zurück zum Zitat Radensky PW, Mango LJ. Interactive neural-network-assisted screening: an economic assessment. Acta Cytol 1998 Jan-Feb; 42 (1): 246–52PubMedCrossRef Radensky PW, Mango LJ. Interactive neural-network-assisted screening: an economic assessment. Acta Cytol 1998 Jan-Feb; 42 (1): 246–52PubMedCrossRef
112.
Zurück zum Zitat Sato S, Matunaga G, Tsuji I, et al. Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models. Acta Cytol 1999 Nov-Dec; 43 (6): 1006–14PubMedCrossRef Sato S, Matunaga G, Tsuji I, et al. Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models. Acta Cytol 1999 Nov-Dec; 43 (6): 1006–14PubMedCrossRef
113.
Zurück zum Zitat Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003 Oct 16; 349 (16): 1501–9PubMedCrossRef Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003 Oct 16; 349 (16): 1501–9PubMedCrossRef
114.
Zurück zum Zitat Schechter CB. Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing. Acta Cytol 1996 Nov-Dec; 40 (6): 1272–82PubMedCrossRef Schechter CB. Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing. Acta Cytol 1996 Nov-Dec; 40 (6): 1272–82PubMedCrossRef
115.
Zurück zum Zitat Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999 Feb 6; 318 (7180): 356–60PubMedCrossRef Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999 Feb 6; 318 (7180): 356–60PubMedCrossRef
116.
Zurück zum Zitat Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK Cervical Cancer Screening Programme. Br J Cancer 2004 Jul 5; 91 (1): 84–91PubMedCrossRef Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK Cervical Cancer Screening Programme. Br J Cancer 2004 Jul 5; 91 (1): 84–91PubMedCrossRef
117.
Zurück zum Zitat Shun-Zhang Y, Miller AB, Sherman GJ. Optimising the age, number of tests, and test interval for cervical screening in Canada. J Epidemiol Community Health 1982 Mar; 36 (1): 1–10PubMedCrossRef Shun-Zhang Y, Miller AB, Sherman GJ. Optimising the age, number of tests, and test interval for cervical screening in Canada. J Epidemiol Community Health 1982 Mar; 36 (1): 1–10PubMedCrossRef
118.
Zurück zum Zitat Sreenivas V, Prabhakar AK, Ravi R, et al. A simulation approach for estimating the loss of woman years due to cervical cancer and probability of developing cervical cancer. Neoplasma 1989; 36 (5): 623–7PubMed Sreenivas V, Prabhakar AK, Ravi R, et al. A simulation approach for estimating the loss of woman years due to cervical cancer and probability of developing cervical cancer. Neoplasma 1989; 36 (5): 623–7PubMed
119.
Zurück zum Zitat van Ballegooijen M, van den Akker-van Marle E, Patnick J, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000 Nov; 36 (17): 2177–88PubMedCrossRef van Ballegooijen M, van den Akker-van Marle E, Patnick J, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000 Nov; 36 (17): 2177–88PubMedCrossRef
120.
Zurück zum Zitat van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002 Feb 6; 94 (3): 193–204PubMedCrossRef van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002 Feb 6; 94 (3): 193–204PubMedCrossRef
121.
Zurück zum Zitat Clemen RT, Lacke CJ. Analysis of colorectal cancer screening regimens. Health Care Manage Sci 2001 Dec; 4 (4): 257–67CrossRef Clemen RT, Lacke CJ. Analysis of colorectal cancer screening regimens. Health Care Manage Sci 2001 Dec; 4 (4): 257–67CrossRef
122.
Zurück zum Zitat Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000 Oct 18; 284 (15): 1954–61PubMedCrossRef Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000 Oct 18; 284 (15): 1954–61PubMedCrossRef
123.
Zurück zum Zitat Gyrd-Hansen D, Søgaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997 Dec; 26 (6): 1172–81PubMedCrossRef Gyrd-Hansen D, Søgaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997 Dec; 26 (6): 1172–81PubMedCrossRef
124.
Zurück zum Zitat Gyrd-Hansen D, Søgaard J, Kronborg O. Colorectal cancer screening: efficiency and effectiveness. Health Econ 1998 Feb; 7 (1): 9–20PubMedCrossRef Gyrd-Hansen D, Søgaard J, Kronborg O. Colorectal cancer screening: efficiency and effectiveness. Health Econ 1998 Feb; 7 (1): 9–20PubMedCrossRef
125.
Zurück zum Zitat Haug U, Brenner H. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2005 Feb; 14 (2): 422–8PubMedCrossRef Haug U, Brenner H. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2005 Feb; 14 (2): 422–8PubMedCrossRef
126.
Zurück zum Zitat Khandker RK, Dulski JD, Kilpatrick JB, et al. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000 Summer; 16 (3): 799–810PubMedCrossRef Khandker RK, Dulski JD, Kilpatrick JB, et al. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000 Summer; 16 (3): 799–810PubMedCrossRef
127.
Zurück zum Zitat Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2001 Nov 6; 135 (9): 769–81PubMed Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2001 Nov 6; 135 (9): 769–81PubMed
128.
Zurück zum Zitat Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003 May; 114 (7): 546–54PubMedCrossRef Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003 May; 114 (7): 546–54PubMedCrossRef
129.
Zurück zum Zitat Lejeune C, Arveux P, Dancourt V, et al. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. Eur J Cancer Prev 2003 Feb; 12 (1): 77–84PubMedCrossRef Lejeune C, Arveux P, Dancourt V, et al. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. Eur J Cancer Prev 2003 Feb; 12 (1): 77–84PubMedCrossRef
130.
Zurück zum Zitat Lejeune C, Arveux P, Dancourt V, et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care 2004 Fall; 20 (4): 434–9PubMedCrossRef Lejeune C, Arveux P, Dancourt V, et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care 2004 Fall; 20 (4): 434–9PubMedCrossRef
131.
Zurück zum Zitat Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999 Feb; 32 (1): 13–33PubMedCrossRef Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999 Feb; 32 (1): 13–33PubMedCrossRef
132.
Zurück zum Zitat Loeve F, Brown ML, Boer R, et al. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000 Apr 5; 92 (7): 557–63PubMedCrossRef Loeve F, Brown ML, Boer R, et al. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000 Apr 5; 92 (7): 557–63PubMedCrossRef
133.
Zurück zum Zitat Loeve F, Boer R, van Oortmarssen GJ, et al. Impact of systematic false-negative test results on the performance of faecal occult blood screening. Eur J Cancer 2001 May; 37 (7): 912–7PubMedCrossRef Loeve F, Boer R, van Oortmarssen GJ, et al. Impact of systematic false-negative test results on the performance of faecal occult blood screening. Eur J Cancer 2001 May; 37 (7): 912–7PubMedCrossRef
134.
Zurück zum Zitat Neilson AR, Whynes DK. Cost-effectiveness of screening for colorectal cancer: a simulation model. IMA J Math Appl Med Biol 1995 Sep-Dec; 12 (3–4): 355–67PubMedCrossRef Neilson AR, Whynes DK. Cost-effectiveness of screening for colorectal cancer: a simulation model. IMA J Math Appl Med Biol 1995 Sep-Dec; 12 (3–4): 355–67PubMedCrossRef
135.
Zurück zum Zitat Ness RM, Holmes AM, Klein R, et al. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000 Jul; 95 (7): 1800–11PubMedCrossRef Ness RM, Holmes AM, Klein R, et al. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000 Jul; 95 (7): 1800–11PubMedCrossRef
136.
Zurück zum Zitat Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004 May; 126 (5): 1270–9PubMedCrossRef Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004 May; 126 (5): 1270–9PubMedCrossRef
137.
Zurück zum Zitat Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001 Dec 1; 111 (8): 593–601PubMedCrossRef Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001 Dec 1; 111 (8): 593–601PubMedCrossRef
138.
Zurück zum Zitat Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991 Nov 15; 115 (10): 807–17PubMed Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991 Nov 15; 115 (10): 807–17PubMed
139.
Zurück zum Zitat Wagner JL, Tunis S, Brown M, et al. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rosen P, Levin B, editors. Prevention and early detection of colorectal cancer. Philadelphia (PA): Saunders, 1996: 321–56 Wagner JL, Tunis S, Brown M, et al. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rosen P, Levin B, editors. Prevention and early detection of colorectal cancer. Philadelphia (PA): Saunders, 1996: 321–56
140.
Zurück zum Zitat Whynes DK, Neilson AR, Walker AR, et al. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ 1998 Feb; 7 (1): 21–9PubMedCrossRef Whynes DK, Neilson AR, Walker AR, et al. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ 1998 Feb; 7 (1): 21–9PubMedCrossRef
141.
Zurück zum Zitat Wong JM, Yen MF, Lai MS, et al. Progression rates of colorectal cancer by Dukes’ stage in a high-risk group: analysis of selective colorectal cancer screening. Cancer J 2004 May-Jun; 10 (3): 160–9PubMedCrossRef Wong JM, Yen MF, Lai MS, et al. Progression rates of colorectal cancer by Dukes’ stage in a high-risk group: analysis of selective colorectal cancer screening. Cancer J 2004 May-Jun; 10 (3): 160–9PubMedCrossRef
142.
Zurück zum Zitat Yang KC, Liao CS, Chiu YH, et al. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen 2006; 13 Suppl. 1: S8–13CrossRef Yang KC, Liao CS, Chiu YH, et al. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen 2006; 13 Suppl. 1: S8–13CrossRef
143.
Zurück zum Zitat Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006 Mar; 10 (8): 1–142PubMed Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006 Mar; 10 (8): 1–142PubMed
144.
Zurück zum Zitat Davies R, Crabbe D, Roderick P, et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manage Sci 2002 Nov; 5 (4): 249–58CrossRef Davies R, Crabbe D, Roderick P, et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manage Sci 2002 Nov; 5 (4): 249–58CrossRef
145.
Zurück zum Zitat Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999 Jan 25; 159 (2): 142–8PubMedCrossRef Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999 Jan 25; 159 (2): 142–8PubMedCrossRef
146.
Zurück zum Zitat Roderick P, Davies R, Raftery J, et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003; 7 (6): 1–86PubMed Roderick P, Davies R, Raftery J, et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003; 7 (6): 1–86PubMed
147.
Zurück zum Zitat Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003; 10 (3): 148–56PubMedCrossRef Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003; 10 (3): 148–56PubMedCrossRef
148.
Zurück zum Zitat Das P, Ng AK, Earle CC, et al. Computed tomography screening for lung cancer in Hodgkin’s lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol 2006 May; 17 (5): 785–93PubMedCrossRef Das P, Ng AK, Earle CC, et al. Computed tomography screening for lung cancer in Hodgkin’s lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol 2006 May; 17 (5): 785–93PubMedCrossRef
149.
Zurück zum Zitat Flehinger BJ, Kimmel M. The natural history of lung cancer in a periodically screened population. Biometrics 1987 Mar; 43 (1): 127–44PubMedCrossRef Flehinger BJ, Kimmel M. The natural history of lung cancer in a periodically screened population. Biometrics 1987 Mar; 43 (1): 127–44PubMedCrossRef
150.
Zurück zum Zitat Flehinger BJ, Kimmel M, Melamed MR. Natural history of adenocarcinoma-large cell carcinoma of the lung: conclusions from screening programs in New York and Baltimore. J Natl Cancer Inst 1988 May 4; 80 (5): 337–44PubMedCrossRef Flehinger BJ, Kimmel M, Melamed MR. Natural history of adenocarcinoma-large cell carcinoma of the lung: conclusions from screening programs in New York and Baltimore. J Natl Cancer Inst 1988 May 4; 80 (5): 337–44PubMedCrossRef
151.
Zurück zum Zitat Flehinger BJ, Kimmel M, Polyak T, et al. Screening for lung cancer: the Mayo Lung Project revisited. Cancer 1993 Sep 1; 72 (5): 1573–80PubMedCrossRef Flehinger BJ, Kimmel M, Polyak T, et al. Screening for lung cancer: the Mayo Lung Project revisited. Cancer 1993 Sep 1; 72 (5): 1573–80PubMedCrossRef
152.
Zurück zum Zitat Gorlova OY, Kimmel M, Henschke C. Modeling of long-term screening for lung carcinoma. Cancer 2001 Sep 15; 92 (6): 1531–40PubMedCrossRef Gorlova OY, Kimmel M, Henschke C. Modeling of long-term screening for lung carcinoma. Cancer 2001 Sep 15; 92 (6): 1531–40PubMedCrossRef
153.
Zurück zum Zitat Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003 Jan 15; 289 (3): 313–22PubMedCrossRef Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003 Jan 15; 289 (3): 313–22PubMedCrossRef
154.
Zurück zum Zitat Marshall D, Simpson KN, Earle CC, et al. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 2001 Jun; 32 (3): 227–36PubMedCrossRef Marshall D, Simpson KN, Earle CC, et al. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 2001 Jun; 32 (3): 227–36PubMedCrossRef
155.
Zurück zum Zitat Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: an approach to lung cancer. Cancer Causes Control 1991 May; 2 (3): 147–55PubMedCrossRef Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: an approach to lung cancer. Cancer Causes Control 1991 May; 2 (3): 147–55PubMedCrossRef
156.
Zurück zum Zitat Yamaguchi N, Mizuno S, Akiba S, et al. A 50-year projection of lung cancer deaths among Japanese males and potential impact evaluation of anti-smoking measures and screening using a computerized simulation model. Jpn J Cancer Res 1992 Mar; 83 (3): 251–7PubMedCrossRef Yamaguchi N, Mizuno S, Akiba S, et al. A 50-year projection of lung cancer deaths among Japanese males and potential impact evaluation of anti-smoking measures and screening using a computerized simulation model. Jpn J Cancer Res 1992 Mar; 83 (3): 251–7PubMedCrossRef
157.
Zurück zum Zitat Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: methodological issues. Environ Health Perspect 1994 Nov; 102 Suppl. 8: 67–71PubMedCrossRef Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: methodological issues. Environ Health Perspect 1994 Nov; 102 Suppl. 8: 67–71PubMedCrossRef
158.
Zurück zum Zitat Girgis A, Clarke P, Burton RC, et al. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 1996; 3 (1): 47–53PubMed Girgis A, Clarke P, Burton RC, et al. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 1996; 3 (1): 47–53PubMed
159.
Zurück zum Zitat Downer MC, Jullien JA, Speight PM. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening. Community Dent Health 1997 Dec; 14 (4): 227–32PubMed Downer MC, Jullien JA, Speight PM. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening. Community Dent Health 1997 Dec; 14 (4): 227–32PubMed
160.
Zurück zum Zitat Myers ER, Havrilesky LJ, Kulasingam SL, et al. Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess (Full Rep) 2006 Oct; (145): 1–100 Myers ER, Havrilesky LJ, Kulasingam SL, et al. Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess (Full Rep) 2006 Oct; (145): 1–100
161.
Zurück zum Zitat Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991; 44 (4–5): 365–80PubMedCrossRef Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991; 44 (4–5): 365–80PubMedCrossRef
162.
Zurück zum Zitat Skates SJ, Pauler DK, Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change point and mixture models of longitudinal markers. J Am Stat Assoc 2001; 96 (454): 429–39CrossRef Skates SJ, Pauler DK, Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change point and mixture models of longitudinal markers. J Am Stat Assoc 2001; 96 (454): 429–39CrossRef
163.
Zurück zum Zitat Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994 Jan; 47 (1): 3–21PubMedCrossRef Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994 Jan; 47 (1): 3–21PubMedCrossRef
164.
Zurück zum Zitat Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 Jun 18; 95 (12): 868–78PubMedCrossRef Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 Jun 18; 95 (12): 868–78PubMedCrossRef
165.
Zurück zum Zitat Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003 Dec; 92 Suppl. 2: 106–11PubMedCrossRef Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003 Dec; 92 Suppl. 2: 106–11PubMedCrossRef
166.
Zurück zum Zitat Draisma G, Postma R, Schroder FH, et al. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006 Nov 15; 119 (10): 2366–71PubMedCrossRef Draisma G, Postma R, Schroder FH, et al. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006 Nov 15; 119 (10): 2366–71PubMedCrossRef
167.
Zurück zum Zitat Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol 1999 Sep; 162 (3 Pt 1): 741–8PubMedCrossRef Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol 1999 Sep; 162 (3 Pt 1): 741–8PubMedCrossRef
168.
Zurück zum Zitat Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999 Jun 16; 91 (12): 1033–9PubMedCrossRef Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999 Jun 16; 91 (12): 1033–9PubMedCrossRef
169.
Zurück zum Zitat Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 Jul 3; 94 (13): 981–90PubMedCrossRef Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 Jul 3; 94 (13): 981–90PubMedCrossRef
170.
Zurück zum Zitat Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer: a decision analytic view. JAMA 1994 Sep 14; 272 (10): 773–80PubMedCrossRef Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer: a decision analytic view. JAMA 1994 Sep 14; 272 (10): 773–80PubMedCrossRef
171.
Zurück zum Zitat Parker C, Muston D, Melia J, et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 May 22; 94 (10): 1361–8PubMedCrossRef Parker C, Muston D, Melia J, et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 May 22; 94 (10): 1361–8PubMedCrossRef
172.
Zurück zum Zitat Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000 Sep 20; 284 (11): 1399–405PubMedCrossRef Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000 Sep 20; 284 (11): 1399–405PubMedCrossRef
173.
Zurück zum Zitat Ross KS, Guess HA, Carter HB. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology 2005 Nov; 66 (5): 1038–42PubMedCrossRef Ross KS, Guess HA, Carter HB. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology 2005 Nov; 66 (5): 1038–42PubMedCrossRef
174.
Zurück zum Zitat Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006 Aug 30; 25 (16): 2846–66PubMedCrossRef Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006 Aug 30; 25 (16): 2846–66PubMedCrossRef
175.
Zurück zum Zitat Kimmel M, Flehinger BJ. Nonparametric estimation of the size-metastasis relationship in solid cancers. Biometrics 1991 Sep; 47 (3): 987–1004PubMedCrossRef Kimmel M, Flehinger BJ. Nonparametric estimation of the size-metastasis relationship in solid cancers. Biometrics 1991 Sep; 47 (3): 987–1004PubMedCrossRef
176.
Zurück zum Zitat Wang PE, Wang TT, Chiu YH, et al. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions? J Med Screen 2006; 13 Suppl. 1: S54–8CrossRef Wang PE, Wang TT, Chiu YH, et al. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions? J Med Screen 2006; 13 Suppl. 1: S54–8CrossRef
177.
Zurück zum Zitat Garrison LP. The ISPOR good practice modeling principles: a sensible approach. Be transparent, be reasonable. Value Health 2003 Jan-Feb; 6 (1): 6–8PubMedCrossRef Garrison LP. The ISPOR good practice modeling principles: a sensible approach. Be transparent, be reasonable. Value Health 2003 Jan-Feb; 6 (1): 6–8PubMedCrossRef
178.
Zurück zum Zitat Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007 July 15, 2007; 166 (2): 137–50CrossRef Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007 July 15, 2007; 166 (2): 137–50CrossRef
180.
Zurück zum Zitat Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation. Report of the ISPOR task force on good research practices: modeling studies. Value Health 2003 Jan-Feb; 6 (1): 9–17PubMedCrossRef Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation. Report of the ISPOR task force on good research practices: modeling studies. Value Health 2003 Jan-Feb; 6 (1): 9–17PubMedCrossRef
Metadaten
Titel
Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
verfasst von
Dr Natasha K. Stout
Amy B. Knudsen
Chung Yin Kong
Pamela M. McMahon
G. Scott Gazelle
Publikationsdatum
01.07.2009
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 7/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/11314830-000000000-00000

Weitere Artikel der Ausgabe 7/2009

PharmacoEconomics 7/2009 Zur Ausgabe